The science behind Happitech

Effective diagnosis means better treatment.

As one of the most common heart conditions, Atrial Fibrillation is a major
medical concern around the world.

1 in 10

individuals over 65 can be affected


of a 10 million population are currently undiagnosed

Risks for undiagnosed patients:


high risk of stroke


higher risk of heart failure


higher risk of cardiovascular mortality

Chest Palpations




Holter Monitoring

Current screening methods can take up to four weeks of consistent monitoring for diagnosis.

As time increases, so does risk. That’s where Happitech technology comes in – providing the
bridge between conventional testing and diagnosis. Identify heart rate abnormalities, establish
patterns of data and support medical diagnosis. All from the comfort of the patient’s own home.

How is Happitech validated?

We’ve achieved full certification and validation for regulatory use across the health and wellness industries. Thanks to our partnerships with the Dutch Patient Association, as well as hospitals such as OLVG and projects such as the CityWide Heart Screening Project, we’ve accomplished what similar services cannot, accurate, clinically-validated monitoring directly through your smartphone.

Research Partners

Mount Sinai logo

Clinical evidence

Through close work with leading medical establishments, Happitech has developed a full
body of clinical evidence to support the benefit and use of our innovative technology for
the monitoring of conditions such as Atrial Fibrillation and heart rate.


For more in-depth insight into the value and functionality of Happitech technology, these
white papers are an excellent place to start.

In the spotlight

Do you have any questions? Check our Support page: